MAPT and Alzheimer disease: For these reasons, a framework for a biological definition of AD emerged, identifying three broad phases: the preclinical AD, mild cognitive impairment (MCI) due to AD, and AD dementia, on the basis of the detection of biomarkers Aβ, tau pathology, and neurodegeneration [17].